STOCK TITAN

MetaVia DA-1726 cuts glucose 43% at low dose in obese mice

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MetaVia Inc. (MTVA) reported preclinical results from a head-to-head study of DA-1726 and retatrutide in diet-induced obese mice treated for approximately three weeks. DA-1726 reduced plasma glucose by 43.0% and 39.2% at low and high doses, respectively, versus 21.5% and 32.5% for retatrutide. After adjustment relative to diet-induced obese controls, body-weight reductions were 34.2% and 41.7% for DA-1726 versus 33.7% and 43.6%; food intake fell 19.6% and 31.2% versus 36.7% and 41.4%. Both treatments improved plasma lipid parameters. At the higher dose, DA-1726 increased hepatic Fgf21 expression (p<0.05), liver FGF21 protein and circulating FGF21 (p<0.001), and expression of thermogenesis-related genes. MetaVia targets a Phase 2, 48-week, non-biopsy study in MetALD and ALD to begin in the second half of 2027.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
DA-1726 plasma glucose reduction 43.0% (low dose); 39.2% (high dose) Head-to-head study in diet-induced obese mice
Retatrutide plasma glucose reduction 21.5% (low dose); 32.5% (high dose) Head-to-head study in diet-induced obese mice
DA-1726 adjusted body-weight reduction 34.2% (low dose); 41.7% (high dose) Adjusted relative to diet-induced obese controls
Retatrutide adjusted body-weight reduction 33.7% (low dose); 43.6% (high dose) Adjusted relative to diet-induced obese controls
DA-1726 food-intake reduction 19.6% (low dose); 31.2% (high dose) Head-to-head study in diet-induced obese mice
Retatrutide food-intake reduction 36.7% (low dose); 41.4% (high dose) Head-to-head study in diet-induced obese mice
Total-cholesterol reduction DA-1726: 70.9% (low dose), 69.3% (high dose); retatrutide: 60.9% (low dose), 69.0% (high dose) Plasma lipid parameters in the mouse study
LDL-cholesterol reduction DA-1726: 89.9% (low dose), 88.4% (high dose); retatrutide: 82.8% (low dose), 88.1% (high dose) Plasma lipid parameters in the mouse study
dual agonist medical
"GLP1R/GCGR dual agonist"
A dual agonist is a single drug designed to activate two different biological targets or pathways at once, like one key that turns two locks to produce a combined effect. For investors, dual agonists can mean the potential for stronger or broader therapeutic benefits and larger market opportunities, but they also carry added development and regulatory risk because safety and effectiveness must be demonstrated for both actions together.
FGF21 medical
"increased hepatic Fgf21 expression and liver FGF21 protein"
FGF21 is a naturally occurring protein hormone that helps control how the body uses sugar, fat and overall energy by sending signals that affect appetite, fat burning and liver function. For investors, FGF21 matters because medicines that mimic or change its activity are a hot area in drug development for diabetes, obesity and liver disease, so clinical progress, safety news or patent moves can meaningfully affect biotech valuations—think of it as a new engine that could change a company’s future performance.
thermogenesis medical
"genes associated with thermogenesis"
Production of heat by a living organism through metabolic processes. Thermogenesis includes shivering (muscle contractions) and non-shivering mechanisms such as activity of brown or beige fat and mitochondrial uncoupling proteins, and it can be triggered by cold exposure, food intake, or certain hormones and drugs; physiologically, it raises energy expenditure without performing external work.
pharmacokinetic exposure estimates technical
"selected based on pharmacokinetic exposure estimates"
MetALD medical
"study in MetALD and ALD"
non-biopsy study medical
"Phase 2, 48-week, non-biopsy study"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did DA-1726 compare with retatrutide in MetaVia’s MTVA preclinical study?

DA-1726 reduced plasma glucose by 43.0% and 39.2% and adjusted body weight by 34.2% and 41.7%, versus 21.5% and 32.5% glucose reductions and 33.7% and 43.6% body-weight reductions for retatrutide at low and high doses, respectively. Food intake fell 19.6% and 31.2% with DA-1726 versus 36.7% and 41.4% with retatrutide.

What doses did MetaVia test for DA-1726 and retatrutide?

The mouse study used twice-weekly subcutaneous injections for approximately three weeks: DA-1726 at 300 or 500 nmol/kg and retatrutide at 100 or 200 nmol/kg. The higher doses were selected using pharmacokinetic exposure estimates intended to approximate clinical exposures at 48 mg for DA-1726 and 12 mg for retatrutide.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001638287false00016382872026-11-142026-11-14

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 14, 2026

Graphic

METAVIA INC.

(Exact name of Registrant as Specified in Its Charter)

​

​

​

​

​

​

Delaware

​

001-37809

​

47-2389984

(State or other jurisdiction

of incorporation)

​

(Commission

File Number)

​

(IRS Employer

Identification No.)

​

​

​

​

​

​

545 Concord Avenue, Suite 210

Cambridge, Massachusetts

​

​

02138

(Address of principal executive offices)

​

(Zip Code)

​

(857) 702-9600

(Registrant’s telephone number, including area code)

​

Not applicable

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

​

Title of each class

  ​ ​ ​

Trading

Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

MTVA

 

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

​

Item 7.01. Regulation FD Disclosures.

On November 16, 2026, MetaVia Inc. (the “Company”) issued a press release announcing positive preclinical data from a head-to-head study comparing DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, with retatrutide, a triple GLP1R/GIPR/GCGR agonist. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.

The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release are as inactive textual references only.

​

Item 8.01. Other Events.

On November 14, 2026, the Company presented positive preclinical data from a head-to-head study comparing DA-1726, a novel dual OXM analog targeting both GLP1R and GCGR, with retatrutide, a triple GLP1R/GIPR/GCGR agonist.

The study evaluated DA-1726 and retatrutide in diet-induced obese mice, assessing body weight, food intake, body composition, plasma metabolic parameters and thermogenesis-related gene expression. Animals received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks. The higher doses were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures at 48 mg for DA-1726 and 12 mg for retatrutide.

DA-1726 demonstrated increased hepatic expression of fibroblast growth factor 21 (Fgf21) along with increased liver FGF21 protein and a numerical increase in circulating FGF21 at the higher dose. DA-1726 also induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning compared with retatrutide. At the higher dose, expression of thermogenesis-related genes, including Ucp1, Ppargc1a and Fgf21, was increased in brown and inguinal white adipose tissue, with several markers demonstrating significantly greater expression than observed with high-dose retatrutide. These findings suggest that glucagon receptor-associated metabolic pathways, including those involving FGF21 and thermogenesis, may contribute to DA-1726’s weight-loss effects.

DA-1726 also demonstrated greater glucose lowering compared with retatrutide, along with favorable effects on lipid metabolism. Plasma glucose levels decreased by 43.0% and 39.2% at the low and high doses, respectively, compared with reductions of 21.5% and 32.5% for retatrutide. Both compounds demonstrated improvements in plasma lipid parameters, with DA-1726 reducing total cholesterol by 70.9% and 69.3%, compared with 60.9% and 69.0% for retatrutide, and LDL cholesterol by 89.9% and 88.4%, compared with 82.8% and 88.1% for retatrutide, respectively. These results demonstrated comparable or numerically greater improvements in glucose and lipid parameters with DA-1726.

In addition, DA-1726 achieved weight loss comparable to retatrutide despite less suppression of food intake. After adjustment relative to the diet-induced obese control group, DA-1726 achieved body weight reductions of 34.2% and 41.7% at the low and high doses, respectively, compared with reductions of 33.7% and 43.6% for retatrutide. However, DA-1726 reduced food intake by 19.6% and 31.2%, compared with 36.7% and 41.4% for retatrutide, respectively. Both treatments also demonstrated comparable effects on body composition, including substantial reductions in fat mass. These findings suggest a potentially greater contribution of glucagon receptor-associated energy expenditure to weight loss with DA-1726 than with retatrutide.

Forward-Looking Statements

This Report, including Exhibit 99.1 attached hereto, contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports that the Company has filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number

 

Exhibit Description

99.1

Press Release dated November 16, 2026.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

​

​

​

​

​

Signatures

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

​

  ​ ​ ​

METAVIA INC.

​

​

​

​

​

​

Date: November 16, 2026

​

By:

/s/ Hyung Heon Kim

​

​

​

Hyung Heon Kim

​

​

​

President and Chief Executive Officer

​

Graphic

Exhibit 99.1

​

​

​

​

​

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

​

Statistically Significant Increase in Liver and Circulating FGF21 Expression

​

Greater Glucose Lowering and Comparable Weight Loss vs. Retatrutide with Less Reliance on Appetite Suppression

​

MetaVia Preparing to Initiate a Phase 2 Study in MetALD and ALD in the Second Half of 2027

​

CAMBRIDGE, Mass., November 16, 2026 – MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study comparing DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. The findings, presented on November 14, 2026, at ObesityWeek® 2026 in Washington, D.C., demonstrated that DA-1726 increased hepatic fibroblast growth factor 21 (Fgf21) gene expression and liver FGF21 protein levels, along with enhanced expression of genes associated with thermogenesis and energy expenditure. DA-1726 also demonstrated greater glucose lowering and achieved weight loss comparable to retatrutide with less suppression of food intake.

​

“Given our focus on liver-related metabolic disease, we are particularly encouraged that DA-1726 increased both gene expression and protein levels of hepatic Fgf21, a key hormone in the regulation of lipid and carbohydrate metabolism.” said Hyung Heon Kim, President and Chief Executive Officer of MetaVia. “Greater glucose lowering and weight loss comparable to retatrutide, despite less suppression of food intake, further support DA-1726’s differentiated metabolic profile. Together with our recent clinical data demonstrating substantial reductions in liver fat and body weight, these findings strengthen the rationale for advancing DA-1726 into a Phase 2 study in MetALD and ALD, targeted to begin in the second half of 2027.”

​

The study compared DA-1726 to retatrutide in diet-induced obese (DIO) mice, assessing body weight, food intake, body composition, plasma metabolic parameters and thermogenesis-related gene expression. Animals received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks. The higher doses were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures at 48 mg for DA-1726 and 12 mg for retatrutide.

DA-1726 demonstrated a statistically significant increase in hepatic expression of Fgf21 (p<0.05), showing both increased liver FGF21 protein and circulating FGF21 (p<0.001) at the higher dose. DA-1726 also induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning compared with retatrutide. At the higher dose, expression of thermogenesis-related genes, including Ucp1, Ppargc1a and Fgf21, was increased in brown and inguinal white adipose tissue, with several markers demonstrating significantly greater expression than observed with high-dose retatrutide. These findings suggest that glucagon receptor-associated metabolic pathways, including those involving FGF21 and thermogenesis, may contribute to DA-1726's weight-loss effects.


​

DA-1726 also demonstrated greater glucose lowering compared with retatrutide, along with favorable effects on lipid metabolism. Plasma glucose levels decreased by 43.0% and 39.2% for DA-1726, versus reductions of 21.5% and 32.5% for retatrutide, at the low and high doses for each compound, respectively. Both showed improvements in plasma lipid parameters, with DA-1726 reducing total cholesterol by 70.9% and 69.3%, compared with 60.9% and 69.0% for retatrutide, and LDL cholesterol by 89.9% and 88.4%, compared with 82.8% and 88.1% for retatrutide, respectively. Comparable or numerically greater improvements in glucose and lipid parameters were consistently observed with DA-1726.

​

In addition, DA-1726 achieved weight loss similar to retatrutide despite less suppression of food intake. After adjustment relative to DIO controls, DA-1726 achieved body weight reductions of 34.2% and 41.7% compared with reductions of 33.7% and 43.6% for retatrutide, at the low and high doses for each compound, respectively. However, DA-1726 reduced food intake by 19.6% and 31.2%, compared with 36.7% and 41.4% for retatrutide, respectively. Both treatments also demonstrated comparable effects on body composition, including substantial reductions in fat mass. These findings suggest a potentially greater contribution of GCGR-associated energy expenditure to weight loss with DA-1726 than with retatrutide.

​

Taken together, these findings highlight DA-1726’s differentiated metabolic profile, demonstrating weight loss comparable to retatrutide with less suppression of food intake, along with increased hepatic Fgf21 expression and protein levels and greater expression of genes associated with thermogenesis. The results suggest that GCGR-associated energy expenditure may play a greater role in DA-1726’s weight-loss effects, providing additional preclinical support for its potential in liver-related cardiometabolic diseases.

​

Presentation Details:

​

●Title: DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide
●Session: Gut Peptides, Appetite Signaling & Novel Therapeutics

Presenting Author: Il Hoon Jeong, MS, Research Scientist, Dong-A ST Research Center

●Poster Number: Poster-229

​

A copy of the poster is available on the Posters section of the MetaVia website.

​

About DA-1726

DA-1726 is a novel GLP1R/GCGR dual agonist being developed to address various cardiometabolic indications, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), which is designed for once weekly, subcutaneous administration. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. It is engineered with a 3:1 GLP1R:GCGR potency ratio intended to balance the complementary effects of GLP1R activation on appetite and glucose control with GCGR activation on energy expenditure and fat breakdown. DA-1726 has a well understood mechanism and preclinical tissue-distribution studies have shown that it concentrates most heavily in adipose tissue and in the liver. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated a 13.5% placebo-adjusted reduction in body weight and a 68.0% placebo-adjusted reduction in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. MetaVia is planning a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027.

​


About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight and 68.0% in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in the second half of 2027. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). It acts directly in the liver on pathways involved in steatosis, inflammation and fibrosis, while GPR119 activation in the pancreas and gut also supports glucose and metabolic regulation. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. MetaVia is advancing vanoglipel in combination with resmetirom as a once-daily oral combination therapy for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027.

​

For more information, please visit www.metaviatx.com.

​

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", “potential”, "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia’s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia’s ability obtain, maintain, protect and/or enforce sufficient intellectual property rights to execute its commercial strategy; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-


looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

​

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer

+1-857-299-1033

marshall.woodworth@metaviatx.com

​

Rx Communications Group

Michael Miller

+1-917-633-6086

mmiller@rxir.com


Filing Exhibits & Attachments

4 documents

Keep reading